Source link : https://www.newshealth.biz/health-news/denosumab-overuse-in-prostate-cancer/
Bone-modifying agents — most notably denosumab — are often prescribed to prevent skeletal-related complications in patients with metastatic castration-sensitive prostate cancer, but the drugs are not recommended for this indication and can lead to severe toxicities. How much does Medicare spend each year on non-recommended bone therapy? The answer, according to a new analysis in […]
Author : News Health
Publish date : 2024-03-04 07:36:54
Copyright for syndicated content belongs to the linked Source.
Categories